Six PD-1/PD-L1 monoclonal antibody (mAb) blockers to date have been approved by FDA for cancer treatment (Postow et al., 2015; Robert et al., 2015; Bang et al., 2018; Tang et al., 2018). This evidence concerns the gene PDCD1 and cancer.